天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>147444-03-9

147444-03-9

中文名稱 啶南平 A
英文名稱 pyripyropene A
CAS 147444-03-9
分子式 C31H37NO10
分子量 583.63
MOL 文件 147444-03-9.mol
147444-03-9 結(jié)構(gòu)式 147444-03-9 結(jié)構(gòu)式

基本信息

中文別名
啶南平 A
英文別名
FO 1289A
pyripyropene A
2H,11H-Naphtho[2,1-b]pyrano[3,4-e]pyran-11-one, 3,6-bis(acetyloxy)-4-[(acetyloxy)methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-9-(3-pyridinyl)-, (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-

物理化學(xué)性質(zhì)

熔點(diǎn)153-154℃
儲(chǔ)存條件Store at -20°C, protect from light, stored under nitrogen
溶解度DMSO: Soluble; Methanol: Soluble
形態(tài)白色至棕色粉末。
顏色Pale pink to rusty brown
啶南平 A價(jià)格(試劑級(jí))
報(bào)價(jià)日期產(chǎn)品編號(hào)產(chǎn)品名稱CAS號(hào)包裝價(jià)格
2024/11/08HY-117832啶南平 A
Pyripyropene A
147444-03-9250 μg4200元

常見問題列表

生物活性
Pyripyropene A 是一種高效、選擇性的 SOAT2/ACAT2 抑制劑,其 IC50 值為 0.07 μM。Pyripyropene A 在體內(nèi)能減輕高膽固醇血癥和動(dòng)脈粥樣硬化。
靶點(diǎn)

IC50: 0.07 μM (ACAT2)

體外研究

Pyripyropene A (0-100 μM; 72 hours) exhibits anti-proliferative activity against HUVECs, and with an IC 50 value of 1.8 μM.
Pyripyropene A (10 μM ; 24 hours) inhibits VEGF (20 ng/ml)-induced migration and tubular formation of HUVECs in dose-dependent fashion.
Pyripyropene A do not show growth inhibitory effects against KB3-1, K562 and Neuro2A cells.

Cell Proliferation Assay

Cell Line: HUVECs
Concentration: 0-100 μM
Incubation Time: 72 hours
Result: Exhibited anti-proliferative activity against HUVECs with an IC 50 value of 1.8 μM.
體內(nèi)研究

Pyripyropene A (10-50 mg/kg per day; p.o; 12 weeks) reduces the levels of plasma cholesterol, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) and hepatic cholesterol content in apolipoprotein E-knockout mice. And Pyripyropene A-treated mice display reduction of atherogenic lesion areas in the aortae and heart.
Pyripyropene A inhibits the hepatic e acyl–coenzyme A:cholesterol acyltransferase 2 (ACAT2) activity in vivo.
Pyripyropene A displays a half-life (t 1/2 ) of 0.693/λ, where λ represented the terminal slope of the log-linear portion of concentration time profile.

Animal Model: Male C57BL/6 mice
Dosage: 0 mg/kg, 1 mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg
Administration: Oral administration; daily; for 12 weeks
Result: Reduced atherogenic lesion areas in the aortae and heart.
Animal Model: 9-week old male ICR mice (pharmacokinetic analysis)
Dosage: 5 mg/kg ,10 mg/kg
Administration: Oral administration
Result: t 1/2 = 0.693/λ
"147444-03-9" 相關(guān)產(chǎn)品信息
2182-55-0 2146-71-6 4704-31-8